器官移植2026，Vol.17Issue(1)：36-43,8.DOI:10.12464/j.issn.1674-7445.2025300
肾移植术后血栓性微血管病诊治进展
Progress in the diagnosis and treatment of thrombotic microangiopathy after kidney transplantation
摘要
Abstract
Thrombotic microangiopathy(TMA)after kidney transplantation is a rare but serious complication characterized by microangiopathic hemolytic anemia,thrombocytopenia and graft dysfunction.It is an important cause of both graft loss and recipient death.The etiology of TMA after kidney transplantation is complex,encompassing calcineurin-inhibitor toxicity,antibody-mediated rejection,infection and drug factors.In recent years,with the in-depth understanding of the core role of the complement system in TMA after kidney transplantation,the application of complement C5 inhibitors(such as eculizumab and ravulizumab)has completely changed the treatment landscape and prognosis of this disease.Therefore,this article aims to provide a systematic review of the progress in the diagnosis and treatment of TMA after kidney transplantation based on the latest literature in recent years,from the aspects of etiology,diagnosis treatment and prognosis,in order to provide a reference for the clinical management of TMA after kidney transplantation.关键词
肾移植/血栓性微血管病/补体/依库珠单抗/雷夫利珠单抗/抗体介导的排斥反应/感染/免疫抑制药Key words
Kidney transplantation/Thrombotic microangiopathy/Complement/Eculizumab/Ravulizumab/Antibody-mediated rejection/Infection/Immunosuppressant分类
医药卫生引用本文复制引用
王晨鸽,李杨..肾移植术后血栓性微血管病诊治进展[J].器官移植,2026,17(1):36-43,8.基金项目
陕西省创新能力支撑计划项目(2025RS-CXTD-054) （2025RS-CXTD-054）
中国器官移植发展基金会课题 （）
